Epitopea key facts
- Developer of transatlantic cancer immunotherapeutics designed to target a novel class of tumor-specific antigens.
- It has raised $44.4M; the latest was Early Stage VC ($31.0M) in Oct 2024.
- Notable investors include Innovate UK, Investissement Quebec, Meltwind Advisory, Jonathan Milner, Fonds de solidarite FTQ — 15 tracked in total.
- Status: Privately Held (backing).
Who backs Epitopea
15+- ·The complete investor list: 15 names
- ·Watch Epitopea: the Monday email on marks, rounds and moves
Epitopea funding rounds
No funding rounds for Epitopea are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Epitopea investors
15 investors are on record for Epitopea, including Innovate UK, Investissement Quebec, Meltwind Advisory and Jonathan Milner.
About Epitopea
Developer of transatlantic cancer immunotherapeutics designed to target a novel class of tumor-specific antigens. The company's technology builds on its proprietary approach to identify shared, expressed tumor-specific antigens and develop immunotherapies that are anticipated to kill malignant cells while sparing non-cancerous cells, enabling healthcare providers to cure cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication with minimal side effects and durable benefits.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2021
- Employees
- 46
- Website
- epitopea.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Epitopea doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.